Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...
Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops
Shares in the pharmaceutical company fell a staggering 85% on Monday after it reported disappointing Phase 3 results, but its ...
GlobalData on MSN6d
Cassava Sciences stock plummets after Phase III Alzheimer’s fail
Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cassava Sciences, Inc. (SAVA) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
thedeepdive5d
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
Fintel on MSN6d
HC Wainwright & Co. Downgrades Cassava Sciences (SAVA)
Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) ...
Cassava Sciences, Inc. Being Investigated on Behalf of Cassava Sciences, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
STAT6d
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...
Yahoo6d
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops
Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Roche's Proposed ...
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals
Cassava Sciences Inc.’s stock tumbled 85% Monday to put it on track for its biggest-ever one-day decline, after the clinical-stage biotech company said a trial of a treatment for mild to moderate ...